For patients and doctors battling chronic resistant infections, Validus Cellular Therapeutics is developing VCT-101, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VCT-101 is a cell therapy to be given with standard of care antibiotic regimens to successfully treat of chronic infections through direct bacterial killing and immune system boosting mechanisms.